Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

This study is testing a combination treatment for liver cancer (hepatocellular carcinoma) that cannot be surgically removed. It combines TACE — a procedure that delivers chemotherapy directly into the blood vessels feeding the tumor while cutting off its blood supply — with two immunotherapy and targeted drugs: adebrelimab (an immunotherapy) and bevacizumab (a drug that blocks blood vessel growth). The study aims to see whether this triple combination is effective and safe. **You may be eligible if...** - You are between 18 and 75 years old with confirmed primary liver cancer (hepatocellular carcinoma) - Your cancer is at an intermediate to advanced but still treatable stage (CNLC Stages IIa–IIIb) - You have not previously received systemic (whole-body) drug treatment for this cancer - Your liver function is relatively preserved (Child-Pugh Grade A or early B) - You have at least one measurable tumor and are well enough to tolerate TACE - If you have active hepatitis B, it must be controlled with antiviral therapy **You may NOT be eligible if...** - You have previously received systemic cancer treatments for liver cancer - Your liver function is severely compromised (Child-Pugh Grade C) - You have autoimmune conditions requiring immune-suppressing medications - You are pregnant or breastfeeding - You have active bleeding disorders or uncontrolled infections Talk to your doctor to see if this trial is right for you.